KIF1A

MARCH 2, 2024

Read the Article Rare Roundup The Jackson Laboratory offers “Exploring Rare Disease Through Translational Research” MiniCourse Human health is incredibly complex; developing safe, effective treatments requires knowledge of molecular mechanisms, cell biology, and drug administration.

Laboratories 119

Laboratories Cell Biology Disease Research 119

Drug Target Review

JULY 13, 2023

The company developed methods to identify disease-driving condensates, model them, and create systems for effective drug discovery targeting these condensates. The aim is to establish condensate biology as a fundamental branch of cell biology – “cell biology 2.0”

Disease 98

Disease Small Molecule Cell Biology Drugs 98

Drug Target Review

SEPTEMBER 19, 2023

Some of the complex 3D models such as organoids and organ-on-chips have brought in realistic make-over to the drug screening and paved way into implementing high content screening, laboratory automation and miniaturisation in primary drug screening process. Trends in Cell Biology. 2011;21(12):745-54. Lab on a Chip.

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98

Drug Target Review

APRIL 9, 2024

Initial works from the lab concentrated on exploring the role of replicative stress in cancer and ageing, for which the group combined cell biology, mouse models and drug development projects. Among other discoveries, the group developed inhibitors of the ATR kinase and showed their potential for cancer therapy.

RNA 64

RNA Cell Biology Clinical Development Disease 64

NIH Director's Blog: Drug Development

SEPTEMBER 20, 2018

Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, Mathiesen JM, Shah ST, Lyons JA, Caffrey M, Gellman SH, Steyaert J, Skiniotis G, Weis WI, Sunahara RK, Kobilka BK. 2011 Jul 19;477(7366):549-55.

Laboratories 52

Laboratories Research Drugs Regulations 52

Codon

APRIL 9, 2024

Tu’s laboratory record lists Artemisia annua L. Department of Defense administered mefloquine, the synthetic drug developed at Walter Reed in the U.S., only issued “the strongest ‘black box’ warning” against the drug in 2013. as Experiment No. to its soldiers for nearly a quarter century.

Drugs 139

Drugs Science Research Doctors 139

Drug Target Review

APRIL 1, 2025

Founded in 2021, SynaptixBio is working to develop therapies for TUBB4A leukodystrophies – a group of rare and severe neurological disorders. Co-founder and CEO Dr Dan Williams brings over 20 years of experience in biochemistry and drug development, with a strong background in research and clinical trials.

Disease 52

Disease Therapies Clinical Trials Cell Biology 52